New Vat CR 500 Tablet
Product Info
Prescription required | Yes |
Marketer | Pulse Pharmaceuticals |
Active Ingredient | Sodium Valproate (333mg) + Valproic Acid (145mg) |
Storage | Store below 30°C |
Habit Forming | No |
Therapeutic Class | NEURO CNS |
User Rating | 4.6 |
User Reviews | 652 |
FAQ
New Vat CR 500 Tablet Reviews
New Vat CR 500 should be taken with food. Your doctor will decide the correct dose for you. This may increase gradually until your condition is stable. This medicine may take several weeks to work but it is important to take it regularly to get the benefit. Do not stop taking it, even if you feel fine unless your doctor advises you to. You may have more seizures, or your bipolar disorder may get worse.
The most common side effects of this medicine are nausea and tremor. In some people, it may also cause other side effetcs like vomiting, headache, liver injury, and upper abdominal pain. Most side effects wear off, but if they bother you or do not go away, tell your doctor. There may be ways of preventing or reducing these effects.
Before taking this medicine, tell your doctor if you have kidney or liver problems, meningitis or depression or suicidal thoughts. Also let your doctor know about all other medications you are using as some may affect, or be affected by, this medicine, including contraceptive pills. If you are pregnant or breastfeeding, New Vat CR 500 can be taken if it is clearly needed but the dose may be adjusted. You should avoid driving or riding a bicycle if this medicine makes you drowsy or dizzy. You may need frequent blood tests to check how you are responding to this medicine.
You should avoid alcohol while taking New Vat CR 500, as it may worsen certain side effects. This medicine can also lead to weight gain, eat a healthy balanced diet, avoid snacking with high-calorie food, and exercise regularly. Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts or behavior.
How New Vat CR 500 Tablet Works
How to Use New Vat CR 500 Tablet
Benefits of New Vat CR 500 Tablet
- In Epilepsy: New Vat CR 500 slows down electrical signals in the brain which cause seizures (fits). It can also help reduce symptoms such as confusion, uncontrollable jerking movements, loss of awareness, and fear or anxiety. The medicine can allow you to do some activities that you would otherwise be forbidden or scared to do (such as swimming and driving). It can take a few weeks for this medicine to work (because the dose has to be increased slowly) and during this time you may still have seizures. Do not stop using this medicine even if you feel well, until your doctor advises you to. Missing doses may trigger a seizure.
Uses of New Vat CR 500 Tablet
- Epilepsy
New Vat CR 500 Tablet Side Effects
Safety Tips
Quick Tips
- Monitor your weight during the treatment as New Vat CR 500 can cause weight gain.
- You have been prescribed New Vat CR 500 for treatment and prevention of seizures.
- Take it at the same time every day to maintain consistent levels in your body.
- Do not drive or do anything that requires mental focus until you know how New Vat CR 500 affects you.
- Your doctor may monitor New Vat CR 500 level, blood counts and liver function regularly throughout your treatment. Inform your doctor if you develop fever, stomach pain, nausea or yellowing of your eyes or skin.
- Avoid consuming alcohol when taking New Vat CR 500, as it may cause excessive sleepiness or drowsiness.
- Do not take New Vat CR 500 if you are pregnant or planning to conceive or breastfeeding.
- Do not stop taking the medication suddenly without talking to your doctor as it may increase the seizure frequency.
References
- Drugs.com. Sodium Valporate.
- Sodium Valproate and Valproic Acid [Package Information]. Gangtok, Sikkim: TORRENT PHARMACEUTICALS LTD.; 2022.
- Drugs.com. Valporic acid.
- Linde M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010611.